Genenta Science S.p.A. (GNTA)
NASDAQ: GNTA · IEX Real-Time Price · USD
3.300
0.00 (0.00%)
At close: May 17, 2024, 4:00 PM
3.270
-0.030 (-0.91%)
After-hours: May 17, 2024, 4:00 PM EDT
Genenta Science Employees
Genenta Science had 14 employees on March 26, 2024. The number of employees increased by 5 or 55.56% compared to the previous year.
Employees
14
Change (1Y)
5
Growth (1Y)
55.56%
Revenue / Employee
n/a
Profits / Employee
-$924,242
Market Cap
60.12M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Mar 26, 2024 | 14 | 5 | 55.56% |
Apr 19, 2023 | 9 | 2 | 28.57% |
Apr 26, 2022 | 7 | 3 | 75.00% |
Sep 15, 2021 | 4 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
GNTA News
- 11 days ago - Genenta Welcomes New Directors John L. Cantello, Lauren H. - GlobeNewsWire
- 3 months ago - Genenta Demonstrated Reprogramming of the Tumor Microenvironment in GBM Patients, Paving the Way for Innovative Treatments of Solid Tumors - GlobeNewsWire
- 9 months ago - Genenta to Present at Upcoming Scientific and Investor Conferences - GlobeNewsWire
- 10 months ago - Genenta Announces Ongoing Clinical Trial Progress and Proposed Expansion in Solid Tumor Treatments - GlobeNewsWire
- 11 months ago - The European Commission Grants Orphan Drug Designation to Temferon™ for Treatment of Glioma - GlobeNewsWire
- 1 year ago - Genenta Announces Fiscal Year 2022 Financial Results and Annual Report on Form 20-F Filing - GlobeNewsWire
- 1 year ago - Genenta Announces Extension of License Agreement with Ospedale San Raffaele to All Solid Tumor Indications - GlobeNewsWire
- 1 year ago - FDA Grants Orphan Drug Designation to Temferon for Treatment of Glioblastoma Multiforme - GlobeNewsWire